Streetbeat News

Stock Prices

GEO

Citron Research predicts that GEO Group Inc. (GEO) will reach $20 in 2024 due to increased funding for border management, implying a need for more prisons, detention centers, and tracking technology.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 3:47 pm

CRC

RBC Capital analyst Scott Hanold has reiterated an Outperform rating on California Resources (NYSE:CRC) and maintained a $60 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 3:47 pm

SO

Southern Inc. (NYSE:SO) stock is currently priced at $71.41, with a slight decrease of 0.01% in the current session. Over the past month, the stock has increased by 2.23%, and over the past year, by 0.66%. The company's P/E ratio of 26.07 is higher than the Electric Utilities industry average of 22.2, suggesting that the stock might be overvalued or that investors expect better future performance and potential dividend increases. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for a comprehensive investment decision.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:46 pm

PBLA

Panbela Therapeutics Inc (NASDAQ:PBLA) stock surged 62% to $1.64 after announcing FDA approval of eflornithine, a drug they divested to US WorldMeds, for high-risk neuroblastoma patients. The approval marks the first for a polyamine targeted therapy in cancer, with Panbela potentially receiving up to $9.5 million based on milestones. The company's executives are optimistic about the drug's impact on neuroblastoma and other cancers. PBLA's 52-week range is $0.45 to $225.71.

Portfolio Pulse from Henry Khederian

December 19, 2023 | 3:40 pm

MCOM

micromobility.com Inc. (NASDAQ:MCOM) received a Nasdaq Delisting Notice due to non-compliance with minimum bid price and stockholders' equity requirements. The company postponed its Special Meeting and withdrew its reverse split request. It is considering whether to appeal the delisting decision, weighing the costs and benefits of Nasdaq listing against potential savings from delisting. MCOM plans to transfer its stock and warrants trading to the OTC markets under the same symbols, with the transition not affecting its business operations or SEC reporting obligations.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 3:40 pm

AZN

CGEN

GILD

Compugen Ltd's stock (CGEN) is trading higher following an agreement with Gilead Sciences Inc (GILD) to license its COM503 drug candidate, a potential first-in-class antibody for cancer immunotherapy. Gilead will pay Compugen $60 million upfront, $30 million upon IND clearance expected in 2024, and up to $758 million in additional payments, plus royalties on net sales. The deal is anticipated to reduce Gilead's 2023 EPS by $0.03-$0.05. Compugen also stands to receive a $10 million milestone payment from AstraZeneca (AZN) for the dosing of the first patient in a trial derived from its COM902 antibody.

Portfolio Pulse from Vandana Singh

December 19, 2023 | 3:36 pm

OSA

ProSomnus Inc (NASDAQ:OSA) stock soared after the publication of a study in the Cureus Journal of Medical Science, which demonstrated the effectiveness of the company's precision oral appliance therapy (OAT) devices for treating obstructive sleep apnea (OSA). The study showed high treatment success rates and strong patient adherence. Additionally, ProSomnus announced further clinical research supporting the efficacy and adherence of their precision OAT devices. As a result, OSA shares surged 73.50% to $1.09.

Portfolio Pulse from Vandana Singh

December 19, 2023 | 3:33 pm

VRTX

Over the past 20 years, Vertex Pharmaceuticals (NASDAQ:VRTX) has produced an average annual return of 20.32%, outperforming the market. A $1000 investment in VRTX 20 years ago would be worth $40,432.16 today. Vertex Pharmaceuticals currently has a market cap of $103.67 billion.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:32 pm

FANG

Over the past decade, Diamondback Energy (NASDAQ:FANG) has delivered an average annual return of 11.54%, outperforming the market. A $100 investment in FANG 10 years ago would now be worth $297.74. The company's current market capitalization stands at $27.76 billion.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:32 pm

BNTX

CVAC

PFE

CureVac N.V's stock plummeted after a German court invalidated a patent central to its lawsuit against BioNTech SE over mRNA COVID-19 vaccine intellectual property rights. The ruling is the first in ongoing litigation involving eight CureVac rights. The decision may delay a separate infringement ruling scheduled for December 2023. CureVac's financial status could transform if awarded a fraction of vaccine revenues. Legal proceedings in the U.S. are also ongoing, with a likely 2024 trial date. Acuitas Therapeutics has also sued CureVac. CVAC shares dropped 33.9%, while BNTX rose 2.69%.

Portfolio Pulse from Vandana Singh

December 19, 2023 | 3:31 pm